Gaithersburg, MD, 25 March 2026 — BullFrog AI (NASDAQ: BFRG) has unveiled bfARENAS, a scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design. The tool completes what the company calls its end-to-end AI intelligence workflow, which runs from data harmonisation (bfPREP) through causal analysis (bfLEAP) to portfolio-level decision-making.
Where most AI tools in biopharma focus on prediction, bfARENAS is designed to support the decision that follows. The platform compares drug programmes, targets, biomarkers, indications and trial designs across multiple real-world scenarios, for instance capital constraints or geographic focus. The aim is to identify resilient programmes rather than just statistically promising ones, balancing portfolio diversity with concentration risk.
The context is a clinical trial failure rate that remains around 90%. BullFrog AI is positioning bfARENAS as a way to turn analytical outputs into decisions that R&D teams can act on with greater confidence, potentially avoiding costly late-stage failures.
For 20 years, pharma has adopted AI tools for discovery and prediction, but none have meaningfully improved decision-making at the portfolio level. bfARENAS closes the loop, transforming AI-powered insights into clear, scenario-tested strategies that real R&D leaders can act on.
The company is hosting a webinar in partnership with Xtalks Life Sciences on 27 March 2026 to demonstrate the platform.
